228

21 / 29

33 - giugno 2017 - Minuti
2013;31(33):4188-4198.
19. Falconer H, et al. Ovarian cancer risk after salpingectomy: a
nationwide population-based study. J Natl Cancer Inst.
2015;107(2):dju410.
20. Friebel TM, Domchek SM, RebbeckTR. Modifiers of cancer
risk in BRCA1 and BRCA2 mutation carriers: systematic review and
meta-analysis [published correction appears in J Natl Cancer Inst.
2014;106(8):dju235]. J Natl Cancer Inst. 2014;106(6):dju091.
21. Goff BA, et al. Frequency of symptoms of ovarian cancer in
women presenting to primary care clinics. JAMA. 2004;291(22):2705-
2712.
22. Goff BA, et al. Development of an ovarian cancer symptom
index: possibilities for earlier detection. Cancer. 2007;109(2):221-
227.
23. Liu JH, Zanotti KM. Management of the adnexal mass. Ob-
stet Gynecol. 2011;117(6):1413-1428.
24. Zhang M, Cheung MK, Shin JY, et al. Prognostic factors re-
sponsible for survival in sex cord stromal tumors of the ovary—an
analysis of 376 women. Gynecol Oncol.2007;104(2):396-400.
25. Ovarian cancer including fallopian tube cancer and primary
peritoneal cancer. 2014.
cian_gls/pdf/ovarian.pdf [login required]. Accessed March 7, 2016.
26. Ameye L, et al. Clinically oriented three-step strategy for as-
sessment of adnexal pathology. Ultrasound Obstet Gynecol.
2012;40(5):582-591.
27. Timmerman D, Ameye L, Fischerova D, et al. Simple ultra-
sound rules to distinguish between benign and malignant adnexal
masses before surgery: prospective validation by IOTA group. BMJ.
2010;341:c6839.
28. Andersen MR, Goff BA, Lowe KA, et al. Use of a Symptom
Index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol.
2010;116(3):378-383.
29. Winter-Roach BA, Kitchener HC, LawrieTA. Adjuvant (post-
surgery) chemotherapy for early stage epithelial ovarian cancer.
Cochrane Database Syst Rev. 2012;(3):CD004706.
30. Vergote I, et al. Neoadjuvant chemotherapy or primary sur-
gery in stage IIICor IVovarian cancer. NEngl JMed. 2010;363(10):943-
953.
31. Goh J, et al. Frontline treatment of epithelial ovarian cancer.
Asia Pac J Clin Oncol. 2015;11(suppl 6):1-16.
32. Buys SS, Partridge E, Black A, et al. Effect of screening on ovar-
ian cancer mortality: the Prostate, Lung, Colorectal and Ovarian
(PLCO) Cancer Screening Randomized Controlled Trial. JAMA.
2011;305(22):2295-2303.
33. Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening
and mortality in the UK Collaborative Trial of Ovarian Cancer
Screening (UKCTOCS): a randomised controlled trial. Lancet.
2015;S0140-6736(15)01224-6.
34. Sharma A, et al. Risk of epithelial ovarian cancer in asymp-
tomatic women with ultrasound-detected ovarian masses: a prospec-
tive cohort study within the UK collaborative trial of ovarian can-
cer screening (UKCTOCS). Ultrasound Obstet Gynecol.
2012;40(3):338-344.
35. AAFP. Clinical preventive services recommendation. Ovarian
cancer. /clinical-recommenda-
tions/all /ovarian-cancer.html. Accessed March 8, 2016.
36. Moyer VA. Risk assessment, genetic counseling, and genetic
testing for
BRCA-related cancer in women: U.S. Preventive Services Task Force
recommendation
statement. Ann Intern Med. 2014;160(4):271-281.
37. QaseemA, Humphrey LL, Harris R, Starkey M, DenbergTD;
Clinical Guidelines Committee of the American College of Physi-
cians. Screening pelvic examination in adult women: a clinical prac-
tice guideline from the American College of Physicians. Ann Intern
Med. 2014;161(1):67-72.
38. Nelson HD, et al. Risk assessment, genetic counseling, and
genetic testing for BRCA-related cancer in women: a systematic re-
view to update the U.S. Preventive Services Task Force recommen-
dation. Ann Intern Med. 2014; 160(4):255-266.
39. Salani R, et al. Posttreatment surveillance and diagnosis of re-
currence in women with gynecologic malignancies: Society of Gy-
necologic Oncologists recommendations. Am J Obstet Gynecol.
2011;204(6):466-478.
40. Radwany SM, von Gruenigen VE. Palliative and end-of-life
care for patients with ovarian cancer. Clin Obstet Gynecol.
2012;55(1):173-184.
41. Mularski RA, et al. A systematic review of measures of end-of-
life care and its outcomes. Health Serv Res. 2007; 42(5):1848-1870.